Becton, Dickinson and Company (NYSE:BDX) Expected to Post Earnings of $2.99 Per Share

Brokerages expect Becton, Dickinson and Company (NYSE:BDXGet Rating) to report $2.99 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Nine analysts have issued estimates for Becton, Dickinson and’s earnings, with the highest EPS estimate coming in at $3.12 and the lowest estimate coming in at $2.75. Becton, Dickinson and reported earnings of $3.19 per share during the same quarter last year, which indicates a negative year over year growth rate of 6.3%. The business is scheduled to report its next quarterly earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Becton, Dickinson and will report full-year earnings of $12.73 per share for the current fiscal year, with EPS estimates ranging from $11.97 to $13.00. For the next fiscal year, analysts forecast that the business will report earnings of $13.50 per share, with EPS estimates ranging from $12.09 to $14.11. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Becton, Dickinson and.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its earnings results on Thursday, February 3rd. The medical instruments supplier reported $3.64 EPS for the quarter, topping the consensus estimate of $2.86 by $0.78. Becton, Dickinson and had a net margin of 8.75% and a return on equity of 14.87%. The business had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.76 billion. During the same period last year, the company earned $4.55 EPS. The firm’s revenue was down 6.0% compared to the same quarter last year.

A number of research analysts have recently issued reports on BDX shares. StockNews.com started coverage on shares of Becton, Dickinson and in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. Bank of America started coverage on shares of Becton, Dickinson and in a research report on Tuesday, March 1st. They issued a “neutral” rating on the stock. Argus boosted their price target on shares of Becton, Dickinson and from $275.00 to $310.00 in a research report on Monday, February 28th. Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and from $275.00 to $285.00 and gave the company an “equal weight” rating in a research note on Friday, April 1st. Finally, SVB Leerink lifted their price objective on shares of Becton, Dickinson and from $270.00 to $275.00 and gave the company a “market perform” rating in a research note on Friday, February 4th. Six investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and currently has a consensus rating of “Hold” and an average target price of $276.25.

Shares of NYSE BDX opened at $247.19 on Friday. The company has a market capitalization of $70.39 billion, a P/E ratio of 42.77, a price-to-earnings-growth ratio of 3.13 and a beta of 0.65. Becton, Dickinson and has a 52-week low of $235.13 and a 52-week high of $280.62. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.78 and a current ratio of 1.23. The company’s 50 day moving average price is $264.95 and its 200-day moving average price is $256.85.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 30th. Shareholders of record on Thursday, June 9th will be paid a dividend of $0.87 per share. This represents a $3.48 dividend on an annualized basis and a yield of 1.41%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 60.21%.

In other news, EVP Betty D. Larson sold 14,374 shares of the company’s stock in a transaction on Friday, February 25th. The shares were sold at an average price of $271.90, for a total value of $3,908,290.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alexandre Conroy sold 6,410 shares of the company’s stock in a transaction on Thursday, February 3rd. The stock was sold at an average price of $270.16, for a total transaction of $1,731,725.60. The disclosure for this sale can be found here. Insiders have sold a total of 21,625 shares of company stock valued at $5,868,516 in the last 90 days. 0.50% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Smith Shellnut Wilson LLC ADV grew its stake in shares of Becton, Dickinson and by 3.2% in the 4th quarter. Smith Shellnut Wilson LLC ADV now owns 1,224 shares of the medical instruments supplier’s stock worth $308,000 after acquiring an additional 38 shares in the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Becton, Dickinson and by 7.8% in the 4th quarter. Global Retirement Partners LLC now owns 541 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 39 shares during the last quarter. Somerset Trust Co boosted its holdings in shares of Becton, Dickinson and by 0.3% in the 1st quarter. Somerset Trust Co now owns 14,459 shares of the medical instruments supplier’s stock worth $3,846,000 after buying an additional 39 shares during the last quarter. Canandaigua National Corp boosted its holdings in shares of Becton, Dickinson and by 0.9% in the 4th quarter. Canandaigua National Corp now owns 4,372 shares of the medical instruments supplier’s stock worth $1,099,000 after buying an additional 40 shares during the last quarter. Finally, SPC Financial Inc. boosted its holdings in shares of Becton, Dickinson and by 4.0% in the 4th quarter. SPC Financial Inc. now owns 1,045 shares of the medical instruments supplier’s stock worth $263,000 after buying an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 84.66% of the company’s stock.

About Becton, Dickinson and (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Read More

Get a free copy of the Zacks research report on Becton, Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.